Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

Artistic representation for Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

* **Rapid Onset of Action:** Anaphylm™ delivers epinephrine quickly and efficiently, with a peak effect within 5 minutes. This rapid onset is crucial for treating life-threatening allergic reactions. * **Sublingual Administration:** Unlike traditional injections, Anaphylm™ can be administered sublingually, meaning it dissolves under the tongue.

Aquestive’s mission is to improve patient lives through innovative science and delivery technologies. This mission is reflected in their commitment to developing and commercializing oral medications that address unmet medical needs. They focus on complex molecules that are difficult to administer through traditional methods, such as injections or intravenous infusions. The company’s core competencies lie in the development of oral drug delivery systems, including:
* **Microencapsulation:** Encapsulating active ingredients in tiny particles to protect them from degradation and improve absorption.

news

news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.

About news

Expert in beauty with years of experience helping people achieve their goals.

View all posts by news →

Leave a Reply

About | Contact | Privacy Policy | Terms of Service | Disclaimer | Cookie Policy
© 2026 WhySkin. All rights reserved.